Sequential versus standard triple first-line therapy for Helicobacter pylori eradication.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 27351542 · doi:10.1002/14651858.CD009034.pub2
What was done
This Cochrane systematic review and meta-analysis evaluated 44 randomized controlled trials (12,284 treatment-naive adult and pediatric participants) published up to April 2015. It compared a 10-day sequential therapy (SEQ: 5 days of PPI plus amoxicillin, followed by 5 days of PPI, clarithromycin, and metronidazole) against standard triple therapy (STT: PPI, clarithromycin, and amoxicillin for 7 to 14 days). Primary outcomes included intention-to-treat (ITT) eradication rates, adverse events, and subgroup variations by treatment duration, geographic region, publication year, and antibiotic resistance, assessed using GRADE methodology.
What was found
SEQ achieved significantly higher overall ITT eradication than STT (82% vs 75%; risk difference [RD] 0.09, 95% CI 0.06 to 0.11; P < 0.001; I² = 75%; moderate-quality evidence). However, SEQ and STT were equivalent when STT was administered for 14 days (high-quality evidence). Eradication superiority for SEQ was pronounced in Europe (RD 0.16, 95% CI 0.14 to 0.19), but reversed in 33% of Asian trials. In trials published in 2008 or later, SEQ efficacy declined at a rate of -1.72% per year (versus -0.9% per year for STT), showing no superiority over 10-day STT. In clarithromycin-resistant infections, SEQ reached 75% eradication versus 43% with STT (very low-quality evidence). Adverse event rates were indistinguishable between groups (20.4% SEQ vs 19.5% STT; RD 0.00, 95% CI -0.02 to 0.02; 27 studies, 8,103 participants; high-quality evidence).
Why it matters
While sequential therapy previously offered an advantage over 7-day triple therapy, its benefit disappears when standard triple therapy is extended to 14 days, and neither regimen reliably achieves the clinical benchmark of ≥90% eradication.
Limits
Primary studies exhibited substantial heterogeneity (I² = 75%) and frequently underreported randomization methods, allocation concealment, and blinding. Evidence regarding clarithromycin resistance was very low quality, geographic representation was uneven, and the efficacy of sequential therapy has progressively eroded in studies published after 2008.
Cited by
- supports Approximately 15% of patients treated with triple antibiotic therapy for Helicobacter pylori cannot tolerate it or do not achieve eradication.